7.40
-0.47(-5.97%)
Currency In USD
| Previous Close | 7.87 |
| Open | 7.95 |
| Day High | 8.05 |
| Day Low | 7.39 |
| 52-Week High | 34.11 |
| 52-Week Low | 5.9 |
| Volume | 1.93M |
| Average Volume | 2.45M |
| Market Cap | 540.14M |
| PE | -11.21 |
| EPS | -0.66 |
| Moving Average 50 Days | 7.26 |
| Moving Average 200 Days | 15.73 |
| Change | -0.47 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $461.06 as of July 15, 2025 at a share price of $7.4. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $209.1 as of July 15, 2025 at a share price of $7.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
GlobeNewswire Inc.
Jul 09, 2025 11:00 AM GMT
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
GlobeNewswire Inc.
Jun 13, 2025 11:00 AM GMT
– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In combination with small molecule inhibitors, ARV-393
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
GlobeNewswire Inc.
Jun 06, 2025 11:00 AM GMT
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITA